Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Genetic variation of hepatitis B virus and its significance for pathogenesis.

Zhang ZH, Wu CC, Chen XW, Li X, Li J, Lu MJ.

World J Gastroenterol. 2016 Jan 7;22(1):126-44. doi: 10.3748/wjg.v22.i1.126. Review.

2.

Long-term follow-up and suboptimal treatment rates of treatment-eligible chronic hepatitis B patients in diverse practice settings: a gap in linkage to care.

Vu VD, Do A, Nguyen NH, Kim LH, Trinh HN, Nguyen HA, Nguyen KK, Nguyen M, Huynh A, Nguyen MH.

BMJ Open Gastroenterol. 2015 Oct 21;2(1):e000060. doi: 10.1136/bmjgast-2015-000060. eCollection 2015.

3.
4.

High dose of Lamivudine and resistance in patients with chronic hepatitis B.

Wani HU, Al Kaabi S, Sharma M, Singh R, John A, Derbala M, Al-Mohannadi MJ.

Hepat Res Treat. 2014;2014:615621. doi: 10.1155/2014/615621. Epub 2014 Sep 30.

5.
6.

HBV and HCV therapy.

Lampertico P, Aghemo A, Viganò M, Colombo M.

Viruses. 2009 Dec;1(3):484-509. doi: 10.3390/v1030484. Epub 2009 Oct 22.

7.

The cost-effectiveness of screening for chronic hepatitis B infection in the United States.

Eckman MH, Kaiser TE, Sherman KE.

Clin Infect Dis. 2011 Jun;52(11):1294-306. doi: 10.1093/cid/cir199. Epub 2011 May 2.

8.

Management of HBV infection during immunosuppressive treatment.

Marzano A.

Mediterr J Hematol Infect Dis. 2009 Dec 22;1(3):e2009025. doi: 10.4084/MJHID.2009.025.

9.

A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective.

Post SE, Sodhi NK, Peng CH, Wan K, Pollack HJ.

Health Aff (Millwood). 2011 Feb;30(2):340-8. doi: 10.1377/hlthaff.2008.0905. Erratum in: Health Aff (Millwood). 2011 Mar;30(3):538.

10.

Should chronic HBV infected patients with normal ALT treated: debate.

Sarin SK, Kumar M.

Hepatol Int. 2008 Jun;2(2):179-84. doi: 10.1007/s12072-008-9065-2. Epub 2008 Mar 4.

11.

DNA-guided hepatitis B treatment, viral load is essential, but not sufficient.

Bárcena Marugán R, García Garzón S.

World J Gastroenterol. 2009 Jan 28;15(4):423-30. Review.

12.

Treatment options for hepatitis B.

Conly J, Johnston B.

Can J Infect Dis Med Microbiol. 2007 May;18(3):173-6. No abstract available.

13.
15.

Characteristics of patients with chronic hepatitis-B virus infection in an urban hospital.

Widjaja D, Yarlagadda S, Singu BS, Loganathan RS, Blum S, Bloom A, Remy P.

J Natl Med Assoc. 2007 Apr;99(4):384-8.

16.

Management of patients with HBeAg-negative chronic hepatitis B.

Saikia N, Talukdar R, Mazumder S, Khanna S, Tandon R.

Postgrad Med J. 2007 Jan;83(975):32-9. Review.

17.

Why adefovir is not yet available in Canada.

Sherman M.

Can J Gastroenterol. 2006 Nov;20(11):694-6. Review. No abstract available.

18.

Screening in liver disease.

Del Poggio P, Mazzoleni M.

World J Gastroenterol. 2006 Sep 7;12(33):5272-80. Review.

19.

Management of HIV/HBV coinfection.

Miller AO.

MedGenMed. 2006 Feb 7;8(1):41. No abstract available.

20.

Lamivudine therapy for children with chronic hepatitis B.

Liberek A, Szaflarska-Popławska A, Korzon M, Łuczak G, Góra-Gebka M, Łoś-Rycharska E, Bako W, Czerwionka-Szaflarska M.

World J Gastroenterol. 2006 Apr 21;12(15):2412-6.

Items per page

Supplemental Content

Write to the Help Desk